http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105153010-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01f7d3d9295f6bf513bd55ec626cf461
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-24
filingDate 2011-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d7d933eab80f0ffb9e4e89776273d2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6701e7075406633627a3f283afd90d8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f40c910165e583409bdb07a862f0d58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b17f57a009ec964a11d8b22105679f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1342c68ac42f2a9fc7b8a29338f0275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f4bf37080ce37f0bf00ff11f900371a
publicationDate 2015-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-105153010-A
titleOfInvention Preparation method of HMG-CoA reductase inhibitor and intermediate thereof
abstract The present invention provides a novel compound containing an amide bond with an R2 - NOR1 group as a key intermediate to prepare HMG-CoA reductase inhibitors such as rosuvastatin calcium, fluvastatin sodium and Improved method of pitavastatin calcium. The present invention also provides novel compounds, intermediates for their preparation, and methods for their preparation.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106905218-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106905218-B
priorityDate 2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008072078-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006106526-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008044243-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465485228
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163931295
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465690724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163790239

Total number of triples: 39.